undefined undefined
NaN.000
NaN.00%
MoonLake Immunotherapeutics press release (NASDAQ:MLTX): Q1 EPS of -$0.22 misses by $0.01. The company ended the quarter with $547.1M in cash More on MoonLake Immunotherapeutics MoonLake Immunotherape...
05-08 00:15
MoonLake (NASDAQ:MLTX) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.20) by 10 percent. This is a 4.35 percent increase over losses of $(0.23) per share from the same
05-07 20:09
Needham:重申MoonLake(MLTX.US)评级,由买入调整至买入评级, 目标价66.00美元。
04-09 18:01
Goldman Sachs has initiated coverage of MoonLake Immunotherapeutics (NASDAQ:MLTX) with a neutral rating, stating that it sees high potential for the company’s drug candidate sonelokimab in the treatme...
04-02 23:21
https://www.betaville.co.uk/betaville-intelligence/uncooked-alert-moonlake-immunotherapeutics-said-to/
03-29 00:02
生物科技投资者看好小盘股,对中盘股的乐观情绪也逐渐升温,并认为Fusion和Merus最有可能在今年跑赢大盘。
02-05 07:37
进入2024年,韦德布什认为生物技术行业早该恢复正增长了,特别是在中小型股。该公司认为临床数据超过关键风险降低点且资产负债表强劲的公司可能最有吸引力。韦德布...
2023-12-15 22:46
Over the past 3 months, 18 analysts have published their opinion on MoonLake (N...
2023-11-27 21:00
MoonLake (NASDAQ:MLTX) reported its Q3 earnings results on Tuesday, November 14...
2023-11-14 22:30